에스비피

DATA

관리자 2020-06-12 조회수 2,029

Adverse Event	WHO Toxicity Criteria Grade (All Casualities, N= 31)
Adverse Event	1	2	3	4	NA	Total
Pyrexia	10 (32.3)	15 (48.4)	0 (0.0)	0 (0.0)	0 (0.0)	25 (80.7)
Feeling cold	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (74.2)	23 (74.2)
Increase in γ -GT	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	12 (38.7)	12 (38.7)
Increase in blood pressure	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10 (32.3)	10 (32.3)
Decrease in Hb	5 (16.1)	3 (9.7)	1 (3.2)	0 (0.0)	0 (0.0)	9 (29.0)
Increase in ALT	4 (12.9)	2 (6.5)	2 (6.5)	0 (0.0)	0 (0.0)	8 (25.9)
Vomiting NOS	0 (0.0)	5 (16.1)	2 (6.5)	0 (0.0)	0 (0.0)	7 (22.6)
Pain NOS	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6 (19.4)	6 (19.4)
Decrease in Platelet count	4 (12.9)	2 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	6 (19.4)
Headache NOS	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6 (19.4)	6 (19.4)
Injection site thrombosis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (16.1)	5 (16.1)
Nausea	5 (16.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (16.1)
Increase in AST	3 (9.7)	0 (0.0)	0 (0.0)	2 (6.5)	0 (0.0)	5 (16.1)
Increase in ALP	4 (12.9)	0 (0.0)	1 (3.2)	0 (0.0)	0 (0.0)	5 (16.1)
Decrease in Blood pressure	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (16.1)	5 (16.1)
Feeling hot	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (12.9)	4 (12.9)
Dizziness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (12.9)	4 (12.9)
Tachycardia NOS	4 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (12.9)

Table 1. Summary of all abnormal reactions (>10%) expressed in Phase 1